How agrressive should lipid lowering be among patients with acute coronary syndromes?

Mahesh Patel, Darren K McGuire

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Results from recent clinical trials have advanced our understanding of the role of HMG-CoA reductase inhibitors (statins) in the management of patients following acute coronary syndrome (ACS) episodes. In aggregate, these trials have demonstrated the safety and efficacy associated with initiation of intensive statin therapy prior to hospital discharge following an ACS episode, independent of baseline low-density lipoprotein (LDL) cholesterol concentrations. Based on the results of these trials, there is now compelling evidence to support intensive lipid lowering with high-dose statins initiated prior to hospital discharge for all patients suffering ACS episodes with a target for LDL cholesterol of 70 mg/dL or lower, recommendations that have been incorporated into clinical practice guideline recommendations in the most recent position statement from the National Cholesterol Education Panel.

Original languageEnglish (US)
Pages (from-to)283-287
Number of pages5
JournalCurrent Cardiology Reports
Volume7
Issue number4
StatePublished - Jul 2005

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Acute Coronary Syndrome
Lipids
LDL Cholesterol
Patient Discharge
Practice Guidelines
Cholesterol
Clinical Trials
Safety
Education
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

How agrressive should lipid lowering be among patients with acute coronary syndromes? / Patel, Mahesh; McGuire, Darren K.

In: Current Cardiology Reports, Vol. 7, No. 4, 07.2005, p. 283-287.

Research output: Contribution to journalArticle

@article{7c104cecdf254664b0afe11f0f124925,
title = "How agrressive should lipid lowering be among patients with acute coronary syndromes?",
abstract = "Results from recent clinical trials have advanced our understanding of the role of HMG-CoA reductase inhibitors (statins) in the management of patients following acute coronary syndrome (ACS) episodes. In aggregate, these trials have demonstrated the safety and efficacy associated with initiation of intensive statin therapy prior to hospital discharge following an ACS episode, independent of baseline low-density lipoprotein (LDL) cholesterol concentrations. Based on the results of these trials, there is now compelling evidence to support intensive lipid lowering with high-dose statins initiated prior to hospital discharge for all patients suffering ACS episodes with a target for LDL cholesterol of 70 mg/dL or lower, recommendations that have been incorporated into clinical practice guideline recommendations in the most recent position statement from the National Cholesterol Education Panel.",
author = "Mahesh Patel and McGuire, {Darren K}",
year = "2005",
month = "7",
language = "English (US)",
volume = "7",
pages = "283--287",
journal = "Current Cardiology Reports",
issn = "1523-3782",
publisher = "Current Medicine Group",
number = "4",

}

TY - JOUR

T1 - How agrressive should lipid lowering be among patients with acute coronary syndromes?

AU - Patel, Mahesh

AU - McGuire, Darren K

PY - 2005/7

Y1 - 2005/7

N2 - Results from recent clinical trials have advanced our understanding of the role of HMG-CoA reductase inhibitors (statins) in the management of patients following acute coronary syndrome (ACS) episodes. In aggregate, these trials have demonstrated the safety and efficacy associated with initiation of intensive statin therapy prior to hospital discharge following an ACS episode, independent of baseline low-density lipoprotein (LDL) cholesterol concentrations. Based on the results of these trials, there is now compelling evidence to support intensive lipid lowering with high-dose statins initiated prior to hospital discharge for all patients suffering ACS episodes with a target for LDL cholesterol of 70 mg/dL or lower, recommendations that have been incorporated into clinical practice guideline recommendations in the most recent position statement from the National Cholesterol Education Panel.

AB - Results from recent clinical trials have advanced our understanding of the role of HMG-CoA reductase inhibitors (statins) in the management of patients following acute coronary syndrome (ACS) episodes. In aggregate, these trials have demonstrated the safety and efficacy associated with initiation of intensive statin therapy prior to hospital discharge following an ACS episode, independent of baseline low-density lipoprotein (LDL) cholesterol concentrations. Based on the results of these trials, there is now compelling evidence to support intensive lipid lowering with high-dose statins initiated prior to hospital discharge for all patients suffering ACS episodes with a target for LDL cholesterol of 70 mg/dL or lower, recommendations that have been incorporated into clinical practice guideline recommendations in the most recent position statement from the National Cholesterol Education Panel.

UR - http://www.scopus.com/inward/record.url?scp=27944509191&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27944509191&partnerID=8YFLogxK

M3 - Article

VL - 7

SP - 283

EP - 287

JO - Current Cardiology Reports

JF - Current Cardiology Reports

SN - 1523-3782

IS - 4

ER -